Efficacy-based perspective to overcome reduced opioid analgesia of advanced painful diabetic neuropathy in rats

Mihály Balogh, Ferenc Zádor, Z. Zádori, Mohammed Shaqura, Kornél Király, Amir Mohammadzadeh, Bence Varga, Bernadette Lázár, Shaaban A. Mousa, Sándor Hosztafi, P. Riba, S. Benyhe, K. Gyires, Michael Schäfer, S. Fürst, M. Al-Khrasani

Research output: Article

1 Citation (Scopus)

Abstract

Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from μ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate (14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9-12 weeks following their systemic administration. The antinociceptive dose-response curve of morphine but not of 14-O-MeM6SU or fentanyl showed a significant right-shift in diabetic compared to non-diabetic rats. Only 14-O-MeM6SU produced antiallodynic effects in doses matching antinociceptive doses obtained in non-diabetic rats. Coadministered naloxone methiodide (NAL-M), a peripherally acting opioid receptor antagonist failed to alter the antiallodynic effect of test compounds, indicating the contribution of central opioid receptors. Reduction in spinal MOR binding sites and loss in MOR immunoreactivity of nerve terminals in the spinal cord and dorsal root ganglia in diabetic rats were observed. G-protein coupling assay revealed low efficacy character for morphine and high efficacy character for 14-O-MeM6SU or fentanyl at spinal or supraspinal levels (Emax values). Furthermore, at the spinal level only 14-O-MeM6SU showed equal efficacy in G-protein activation in tissues of diabetic- and non-diabetic animals. Altogether, the reduction of spinal opioid receptors concomitant with reduced analgesic effect of morphine may be circumvented by using high efficacy opioids, which provide superior analgesia over morphine. In conclusion, the reduction in the analgesic action of opioids in DNP might be a consequence of MOR reduction, particularly in the spinal cord. Therefore, developing opioids of high efficacy might provide analgesia exceeding that of currently available opioids.

Original languageEnglish
Article number347
JournalFrontiers in Pharmacology
Volume10
Issue numberAPR
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Diabetic Neuropathies
Analgesia
Opioid Analgesics
Morphine
Sulfates
Opioid Receptors
Neuralgia
Fentanyl
GTP-Binding Proteins
Spinal Cord
Narcotic Antagonists
Spinal Nerve Roots
Spinal Ganglia
Streptozocin
Analgesics
Binding Sites

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Efficacy-based perspective to overcome reduced opioid analgesia of advanced painful diabetic neuropathy in rats. / Balogh, Mihály; Zádor, Ferenc; Zádori, Z.; Shaqura, Mohammed; Király, Kornél; Mohammadzadeh, Amir; Varga, Bence; Lázár, Bernadette; Mousa, Shaaban A.; Hosztafi, Sándor; Riba, P.; Benyhe, S.; Gyires, K.; Schäfer, Michael; Fürst, S.; Al-Khrasani, M.

In: Frontiers in Pharmacology, Vol. 10, No. APR, 347, 01.01.2019.

Research output: Article

Balogh, Mihály ; Zádor, Ferenc ; Zádori, Z. ; Shaqura, Mohammed ; Király, Kornél ; Mohammadzadeh, Amir ; Varga, Bence ; Lázár, Bernadette ; Mousa, Shaaban A. ; Hosztafi, Sándor ; Riba, P. ; Benyhe, S. ; Gyires, K. ; Schäfer, Michael ; Fürst, S. ; Al-Khrasani, M. / Efficacy-based perspective to overcome reduced opioid analgesia of advanced painful diabetic neuropathy in rats. In: Frontiers in Pharmacology. 2019 ; Vol. 10, No. APR.
@article{261f5590eaed4784b4573e481ee7292f,
title = "Efficacy-based perspective to overcome reduced opioid analgesia of advanced painful diabetic neuropathy in rats",
abstract = "Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from μ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate (14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9-12 weeks following their systemic administration. The antinociceptive dose-response curve of morphine but not of 14-O-MeM6SU or fentanyl showed a significant right-shift in diabetic compared to non-diabetic rats. Only 14-O-MeM6SU produced antiallodynic effects in doses matching antinociceptive doses obtained in non-diabetic rats. Coadministered naloxone methiodide (NAL-M), a peripherally acting opioid receptor antagonist failed to alter the antiallodynic effect of test compounds, indicating the contribution of central opioid receptors. Reduction in spinal MOR binding sites and loss in MOR immunoreactivity of nerve terminals in the spinal cord and dorsal root ganglia in diabetic rats were observed. G-protein coupling assay revealed low efficacy character for morphine and high efficacy character for 14-O-MeM6SU or fentanyl at spinal or supraspinal levels (Emax values). Furthermore, at the spinal level only 14-O-MeM6SU showed equal efficacy in G-protein activation in tissues of diabetic- and non-diabetic animals. Altogether, the reduction of spinal opioid receptors concomitant with reduced analgesic effect of morphine may be circumvented by using high efficacy opioids, which provide superior analgesia over morphine. In conclusion, the reduction in the analgesic action of opioids in DNP might be a consequence of MOR reduction, particularly in the spinal cord. Therefore, developing opioids of high efficacy might provide analgesia exceeding that of currently available opioids.",
keywords = "14-O-methylmorphine-6-O-sulfate, Diabetes, Fentanyl, Morphine, Neuropathic pain, Opioid efficacy",
author = "Mih{\'a}ly Balogh and Ferenc Z{\'a}dor and Z. Z{\'a}dori and Mohammed Shaqura and Korn{\'e}l Kir{\'a}ly and Amir Mohammadzadeh and Bence Varga and Bernadette L{\'a}z{\'a}r and Mousa, {Shaaban A.} and S{\'a}ndor Hosztafi and P. Riba and S. Benyhe and K. Gyires and Michael Sch{\"a}fer and S. F{\"u}rst and M. Al-Khrasani",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fphar.2019.00347",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Efficacy-based perspective to overcome reduced opioid analgesia of advanced painful diabetic neuropathy in rats

AU - Balogh, Mihály

AU - Zádor, Ferenc

AU - Zádori, Z.

AU - Shaqura, Mohammed

AU - Király, Kornél

AU - Mohammadzadeh, Amir

AU - Varga, Bence

AU - Lázár, Bernadette

AU - Mousa, Shaaban A.

AU - Hosztafi, Sándor

AU - Riba, P.

AU - Benyhe, S.

AU - Gyires, K.

AU - Schäfer, Michael

AU - Fürst, S.

AU - Al-Khrasani, M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from μ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate (14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9-12 weeks following their systemic administration. The antinociceptive dose-response curve of morphine but not of 14-O-MeM6SU or fentanyl showed a significant right-shift in diabetic compared to non-diabetic rats. Only 14-O-MeM6SU produced antiallodynic effects in doses matching antinociceptive doses obtained in non-diabetic rats. Coadministered naloxone methiodide (NAL-M), a peripherally acting opioid receptor antagonist failed to alter the antiallodynic effect of test compounds, indicating the contribution of central opioid receptors. Reduction in spinal MOR binding sites and loss in MOR immunoreactivity of nerve terminals in the spinal cord and dorsal root ganglia in diabetic rats were observed. G-protein coupling assay revealed low efficacy character for morphine and high efficacy character for 14-O-MeM6SU or fentanyl at spinal or supraspinal levels (Emax values). Furthermore, at the spinal level only 14-O-MeM6SU showed equal efficacy in G-protein activation in tissues of diabetic- and non-diabetic animals. Altogether, the reduction of spinal opioid receptors concomitant with reduced analgesic effect of morphine may be circumvented by using high efficacy opioids, which provide superior analgesia over morphine. In conclusion, the reduction in the analgesic action of opioids in DNP might be a consequence of MOR reduction, particularly in the spinal cord. Therefore, developing opioids of high efficacy might provide analgesia exceeding that of currently available opioids.

AB - Reduction of the opioid analgesia in diabetic neuropathic pain (DNP) results from μ-opioid receptor (MOR) reserve reduction. Herein, we examined the antinociceptive and antiallodynic actions of a novel opioid agonist 14-O-methymorphine-6-O-sulfate (14-O-MeM6SU), fentanyl and morphine in rats with streptozocin-evoked DNP of 9-12 weeks following their systemic administration. The antinociceptive dose-response curve of morphine but not of 14-O-MeM6SU or fentanyl showed a significant right-shift in diabetic compared to non-diabetic rats. Only 14-O-MeM6SU produced antiallodynic effects in doses matching antinociceptive doses obtained in non-diabetic rats. Coadministered naloxone methiodide (NAL-M), a peripherally acting opioid receptor antagonist failed to alter the antiallodynic effect of test compounds, indicating the contribution of central opioid receptors. Reduction in spinal MOR binding sites and loss in MOR immunoreactivity of nerve terminals in the spinal cord and dorsal root ganglia in diabetic rats were observed. G-protein coupling assay revealed low efficacy character for morphine and high efficacy character for 14-O-MeM6SU or fentanyl at spinal or supraspinal levels (Emax values). Furthermore, at the spinal level only 14-O-MeM6SU showed equal efficacy in G-protein activation in tissues of diabetic- and non-diabetic animals. Altogether, the reduction of spinal opioid receptors concomitant with reduced analgesic effect of morphine may be circumvented by using high efficacy opioids, which provide superior analgesia over morphine. In conclusion, the reduction in the analgesic action of opioids in DNP might be a consequence of MOR reduction, particularly in the spinal cord. Therefore, developing opioids of high efficacy might provide analgesia exceeding that of currently available opioids.

KW - 14-O-methylmorphine-6-O-sulfate

KW - Diabetes

KW - Fentanyl

KW - Morphine

KW - Neuropathic pain

KW - Opioid efficacy

UR - http://www.scopus.com/inward/record.url?scp=85068475051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068475051&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00347

DO - 10.3389/fphar.2019.00347

M3 - Article

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - APR

M1 - 347

ER -